News and Articles
Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.
Featured article
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Newly added funding closes critical gap and enables planned trial initiation in early 2026
Latest Posts
Breaking Down a Breakthrough: A New Way to Help the Eye Heal Itself
Scientists have discovered that blocking a protein called Prox1 may allow the eye to repair itself. This breakthrough could open the door to regenerative therapies for vision loss caused by diseases like retinitis pigmentosa.
Beyond Fundraising: How Our Ads Build Awareness and Community
💡 Awareness Through Advertising Our ad campaigns are about more than prizes. They spark awareness for Bardet-Biedl Syndrome, connect us daily with families across rare disease and vision loss communities, and help lift up the work of other nonprofits. Every ad is a chance to build awareness, connection, and impact.
A Major Step Forward: Ocugen Launches Phase 2/3 Trial of OCU410ST for Stargardt Disease
🚀 Hope for Stargardt Disease Ocugen has announced FDA clearance to begin a Phase 2/3 trial of OCU410ST, a groundbreaking modifier gene therapy for Stargardt disease. Early results show slowed disease progression and vision improvements, bringing real hope to the 1 million people worldwide affected by this inherited condition.
Stem Cell–Derived Retinal Sheets Enter Clinical Trial for Retinitis Pigmentosa
Stem Cell–Derived Retinal Sheets Trial for RP A new clinical trial is testing DSP-3077, a one-time stem cell–derived retinal sheet implant, as a potential treatment for retinitis pigmentosa. This regenerative therapy could offer hope for patients regardless of genetic subtype. Learn how this groundbreaking study may shape the future of RP treatment.
Nanoscope Therapeutics Advances One-Time Gene Therapy for Retinitis Pigmentosa and Stargardt Disease
Hope for RP and Stargardt Disease Nanoscope Therapeutics is advancing a one-time gene therapy designed to restore vision for patients with retinitis pigmentosa and Stargardt disease. If successful, this treatment could transform care for two conditions that currently have no approved therapies.